var data={"title":"Propranolol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Propranolol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6861?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=propranolol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Propranolol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=propranolol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Propranolol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7254284\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiac ischemia after abrupt discontinuation (Inderal LA, Inderal XL, Innopran XL):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Following abrupt discontinuation of therapy with beta-blockers, exacerbations of angina pectoris and myocardial infarction (MI) have occurred.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">When discontinuing long-term administration of propranolol, particularly in patients with ischemic heart disease, gradually reduce the dose over a period of 1 to 2 weeks and monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, promptly resume therapy, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without health care provider's advice.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because coronary artery disease is common and may be unrecognized, avoid abrupt discontinuation of propranolol therapy, even in patients treated only for hypertension.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214907\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hemangeol;</li>\n      <li>Inderal LA;</li>\n      <li>Inderal XL;</li>\n      <li>InnoPran XL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214908\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Propranolol;</li>\n      <li>Dom-Propranolol;</li>\n      <li>Hemangiol;</li>\n      <li>Inderal LA;</li>\n      <li>PMS-Propranolol;</li>\n      <li>Propranolol Hydrochloride Injection, USP;</li>\n      <li>Teva-Propranolol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214939\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Antiarrhythmic Agent, Class II;</li>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Beta-Blocker, Nonselective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214911\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential tremor:</b> Oral: Immediate-release formulations: 40 mg twice daily initially; maintenance doses: Usually 120 to 320 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release formulations: 40 mg twice daily; increase dosage every 3 to 7 days; usual dose: 120 to 240 mg divided in 2 to 3 doses/day; maximum daily dose: 640 mg; usual dosage range (ASH/ISH [Weber 2014]): 40 to 160 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release formulations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inderal LA: Initial: 80 mg once daily; usual maintenance: 120 to 160 mg once daily; maximum daily dose: 640 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inderal XL, InnoPran XL: Initial: 80 mg once daily at bedtime; if initial response is inadequate, may be increased at 2 to 3 week intervals to a maximum daily dose of 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine headache prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release formulations: Initial: 80 mg/day divided every 6 to 8 hours; increase by 20 to 40 mg/dose every 3 to 4 weeks to a maximum of 160 to 240 mg/day given in divided doses every 6 to 8 hours; if satisfactory response not achieved within 6 weeks of starting therapy, drug should be withdrawn gradually over several weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inderal LA: Initial: 80 mg once daily; effective dose range: 160 to 240 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obstructive hypertrophic cardiomyopathy: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release formulations: 20 to 40 mg 3 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inderal LA: 80 to 160 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pheochromocytoma:</b> Oral: Immediate-release formulations: 30 to 60 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-MI mortality reduction:</b> Oral: Immediate-release formulations: Initial: 40 mg 3 times/day; usual dosage range: 180 to 240 mg/day in 3 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stable angina:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release formulations: 80 to 320 mg/day in doses divided 2 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inderal LA: Initial: 80 mg once daily; maximum dose: 320 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment (off-label dose):</i> IV: Initial: 1 mg over 1 minute, may repeat 1 mg after 2-minute intervals, up to 3 doses (ACC/AHA/HRS [Page 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ongoing management (off-label use): </i>Oral: Initial: 30 to 60 mg daily in divided doses (immediate-release) or once daily (extended-release); maximum maintenance dose: 160 mg daily in divided doses (immediate-release) or once daily (extended-release) (ACC/AHA/HRS [Page 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tachyarrhythmias:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate-release formulations: 10 to 30 mg/dose every 6 to 8 hours or a usual maintenance dose of 10 to 40 mg three or four times daily for rate control in patients with atrial fibrillation (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 to 3 mg/dose slow IVP; repeat every 2-5 minutes up to a total of 5 mg; titrate initial dose to desired response. <b>Note:</b> Once response achieved or maximum dose administered, additional doses should not be given for at least 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.5 to 1 mg over 1 minute; may repeat, if necessary, up to a total maximum dose of 0.1 mg/kg (ACLS guidelines 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 mg over 1 minute; may be repeated every 2 minutes up to 3 doses for rate control in patients with atrial fibrillation (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Akathisia, antipsychotic-induced (off-label use):</b> Oral: Immediate-release formulations: Initial: 10 mg twice daily <b>or</b> 10 mg 3 times daily; adjust dose based on response and tolerability up to 120 mg/day (Adler 1986; Adler 1993; Kane 2009; Kramer 1989). Treatment guidelines recommend doses of 30 to 90 mg/day (APA [Lehman 2004]; WFSBP [Hasan 2013].</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Performance anxiety (off-label use):</b> Oral: Immediate-release formulations: 40 mg 60 to 90 minutes prior to anxiety-provoking event (Hartley 1983). Additional data may be necessary to further define the role of propranolol in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid storm (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate-release formulations: 60 to 80 mg every 4 hours (ATA [Ross 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.5 to 1 mg administered over 10 minutes followed by 1 to 3 mg over 10 to 15 minutes every several hours with continuous cardiac monitoring; when transitioning to oral therapy, IV therapy may need to be continued until the effects of oral therapy are achieved (Braverman 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxicosis (off-label use):</b> Oral: Immediate-release formulations: 10 to 40 mg every 6 to 8 hours; may also consider administering once-daily extended or sustained release formulations (ATA [Ross 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tremor, lithium-induced (off-label use):</b> Oral: Immediate-release formulations: 30 to 80 mg/day in divided doses; adjust dose based on response and tolerability (Gelenberg 1995; Kirk 1973; Lapierre 1976). Additional data may be necessary to further define the role of propranolol in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Variceal hemorrhage prophylaxis (off-label use)</b> (AASLD [Garcia-Tsao 2007]): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Primary prophylaxis: Immediate-release formulations: Initial: 20 mg twice daily; adjust to maximal tolerated dose. <b>Note:</b> Risk factors for hemorrhage include Child-Pugh class B/C or variceal red wale markings on endoscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Secondary prophylaxis: Immediate-release formulations: Initial: 20 mg twice daily; adjust to maximal tolerated dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214926\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=propranolol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Propranolol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Proliferating infantile hemangioma (Hemangeol):</b> Infants &ge;2 kg: Oral: <b>Note:</b> Initiate treatment at age 5 weeks to 5 months; doses should be administered at least 9 hours apart. Refer to product labeling for detailed weight-based dosing tabulation. Dosing expressed in terms of salt. Propranolol hydrochloride 4.28 mg/mL is equivalent to propranolol base 3.75 mg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 1: 0.15 mL/kg (~0.6 mg/kg) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 2: 0.3 mL/kg (~1.1 mg/kg) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 3 (maintenance): 0.4 mL/kg (~1.7 mg/kg) twice daily; maintain this dose for 6 months. Readjust dose periodically as the child's weight increases. Treatment may be reinitiated if hemangiomas recur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension (off-label use):</b> Children and Adolescents: Oral: Immediate-release formulations: Initial: 1 to 2 mg/kg/day divided in 2 to 3 doses/day; titrate dose to effect; maximum dose: 4 mg/kg/day up to 640 mg/day; sustained-release formulation may be dosed once daily (NHBPEP 2004; NHLBI 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxicosis (off-label use):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Oral: Immediate release formulations: 0.5 to 2 mg/kg/day divided every 8 hours; maximum dose: 40 mg/dose (Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid storm:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Oral: 1 to 4 mg/kg/day divided every 12 hours (Cameron 2012; Fuhrman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release formulations: 20 to 40 mg every 4 to 6 hours (Kliegman, 2016); doses as high as 60 to 80 mg every 4 hours have been recommended (ATA [Ross 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.5 to 1 mg slow IV push over 10 minutes (Braverman 2013, Kliegman 2016). Dosing interval in adolescents is not defined; in adults, doses may be repeated every several hours with continuous cardiac monitoring; when transitioning to oral therapy, IV therapy may need to be continued until the effects of oral therapy are achieved (Braverman 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214912\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Use caution; initiate at lower end of the dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension: Consider lower initial doses and titrate to response (Aronow 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tachyarrhythmias: Immediate-release formulations: Initial: 10 mg twice daily; increase dosage every 3 to 7 days; usual dose range: 10 to 320 mg/day given in 1 to 2 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Refer to adult dosing for additional uses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214913\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, renal impairment increases systemic exposure to propranolol. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Not dialyzable (0% to 5%); supplemental dose is not necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis effects: Supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214914\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, hepatic impairment increases systemic exposure to propranolol. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214877\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inderal LA: 60 mg, 80 mg, 120 mg, 160 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inderal XL: 80 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">InnoPran XL: 80 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg, 80 mg, 120 mg, 160 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemangeol: 4.28 mg/mL (120 mL) [alcohol free, paraben free, sugar free; contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/5 mL (500 mL); 40 mg/5 mL (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214862\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573739\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Prescriptions for Hemangeol may be obtained via the Hemangeol Patient Access program.  Visit http://www.hemangeol.com/hcp/hemangeol-direct/ or call 855-618-4950 for ordering information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214882\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: IV dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure. May administer by rapid infusion (IV push) at a rate of 1 mg/minute or by slow infusion over ~30 minutes. Necessary monitoring for surgical patients who are unable to take oral beta-blockers (prolonged ileus) has not been defined. Some institutions require monitoring of baseline and postinfusion heart rate and blood pressure when a patient's response to beta-blockade has not been characterized (ie, the patient's initial dose or following a change in dose). Consult individual institutional policies and procedures. Do not crush long-acting oral forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablets (immediate release) should be taken on an empty stomach; capsules (extended release) may be taken with or without food, but should always be taken consistently (with food or on an empty stomach). Do not crush long-acting oral forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemangeol should be administered during or right after a feeding to reduce the risk of hypoglycemia; skip dose if child is not eating or is vomiting. Administer doses at least 9 hours apart. Do not shake Hemangeol before use. Administer Hemangeol directly into the child&rsquo;s mouth using the supplied oral dosing syringe; if needed, may be diluted with a small quantity of milk or fruit juice and given in a baby&rsquo;s bottle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214881\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of hypertension; angina pectoris; pheochromocytoma; essential tremor; supraventricular arrhythmias (such as atrial fibrillation and flutter, AV nodal re-entrant tachycardias), ventricular tachycardias (catecholamine-induced arrhythmias, digoxin toxicity); prevention of myocardial infarction; migraine headache prophylaxis; symptomatic treatment of obstructive hypertrophic cardiomyopathy (formerly known as hypertrophic subaortic stenosis); treatment of proliferating infantile hemangioma requiring systemic therapy (Hemangeol only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension: The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James 2013]): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;60 years of age, with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &lt;60 years of age, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years of age with diabetes, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years of age with chronic kidney disease (CKD), with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker <b>instead of</b> an ACEI or ARB. Beta-blockers are no longer recommended as first-line therapy in the general patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology, and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with CAD recommends the use of a beta blocker as part of a regimen in patients with hypertension and chronic stable angina with a history of prior MI. A BP target of &lt;140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (&lt;130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents (AHA/ACC/ASH [Rosendorff 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744560\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Akathisia, antipsychotic-induced; Performance anxiety; Supraventricular tachycardia (atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, atrial flutter, focal atrial tachycardia, multifocal atrial tachycardia) (oral); Thyroid storm; Thyrotoxicosis; Tremor, lithium-induced; Variceal hemorrhage (prophylaxis); Tetralogy of Fallot (TOF) hypercyanotic spells; Thyrotoxicosis/thyroid storm (pediatric patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214948\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Propranolol may be confused with prasugrel, Pravachol, Propulsid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Inderal may be confused with Adderall, Enduron, Imdur, Imuran, Inderide, Isordil, Toradol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Deralin [Australia, Israel] may be confused with Deptran brand name for doxepin [Australia]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Inderal [Canada and multiple international markets], Inderal LA [U.S.], and Inderal XL [U.S.] may be confused with Indiaral brand name for loperamide [France] or Indamol brand name for indapamide [Italy]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214869\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cold extremities (infants: 7% to 8%), angina pectoris, atrioventricular conduction disturbance, bradycardia, cardiac failure, cardiogenic shock, hypotension, ineffective myocardial contractions, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Sleep disorder (infants: 16% to 18%), agitation (infants: 5% to 9%), fatigue (5% to 7%), dizziness (4% to 7%), nightmares (infants: 2% to 6%), irritability (infants: 1% to 6%), drowsiness (infants: 1% to 5%), amnesia, carpal tunnel syndrome (rare), catatonia, cognitive dysfunction, confusion, hypersomnia, lethargy, paresthesia, psychosis, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Changes in nails, contact dermatitis, dermal ulcer, eczematous rash, erosive lichen planus, hyperkeratosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia, hyperlipidemia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (infants: 5% to 6%), abdominal pain (infants: &le;4%), decreased appetite (infants: 3% to 4%), constipation (1% to 3%), anorexia, stomach discomfort</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Oliguria (rare), proteinuria (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Immune thrombocytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthropathy, oculomucocutaneous syndrome, polyarthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival hyperemia, decreased visual acuity, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, interstitial nephritis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis (infants: 8% to 13%; associated with cough, fever, diarrhea, and vomiting), bronchiolitis (infants; associated with cough, fever, diarrhea, and vomiting), bronchospasm, dyspnea, pulmonary edema, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Ulcer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, agranulocytosis, alopecia, altered mental status, arterial insufficiency, arterial mesenteric thrombosis, decreased heart rate (infants), decreased serum glucose (infants), depression, emotional lability, epigastric distress, erythema multiforme, erythematous rash, exfoliative dermatitis, fever combined with generalized ache, sore throat, laryngospasm, and respiratory distress), hallucination, hypersensitivity reaction (including anaphylaxis, anaphylactoid reaction), impotence, insomnia, ischemic colitis, lassitude, lupus-like syndrome, myotonia, myopathy, nausea, nonthrombocytopenic purpura, peripheral arterial disease (exacerbation), Peyronie's disease, pharyngitis, psoriasiform eruption, purpura, Raynaud's phenomenon, second degree atrioventricular block (infants; in a patient with an underlying conduction disorder), Stevens-Johnson syndrome, systemic lupus erythematosus, temporary amnesia, tingling of extremities (hands), toxic epidermal necrolysis, urticaria, visual disturbance, vivid dream, vomiting, weakness, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214885\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to propranolol, beta-blockers, or any component of the formulation; uncompensated congestive heart failure (unless the failure is due to tachyarrhythmias being treated with propranolol), cardiogenic shock; severe sinus bradycardia, sick sinus syndrome, or heart block greater than first-degree (except in patients with a functioning artificial pacemaker); bronchial asthma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemangeol (additional contraindications): Premature infants with corrected age &lt;5 weeks; infants weighing &lt;2 kg; heart rate &lt;80 bpm; blood pressure &lt;50/30 mm Hg; pheochromocytoma; history of bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Cor pulmonale; allergic rhinitis during pollen season; patients prone to hypoglycemia; hypotension (blood pressure parameters not specified in labeling); metabolic acidosis; vasospastic angina (also referred to as Prinzmetal angina or variant angina); severe peripheral arterial circulatory disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemangiol (additional contraindications): Infants weighing &lt;2.5 kg; breastfed infants if mother is treated with medicines contraindicated with propranolol; heart rate &lt;100 bpm or blood pressure &lt;65/45 mm Hg (&lt;3 months of age), heart rate &lt;90 bpm or blood pressure &lt;70/50 mm Hg (3 to &lt;6 months of age), heart rate &lt;80 bpm or blood pressure &lt;80/55 mm Hg (6 to 12 months of age)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214866\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Use with caution in patients with compensated HF and monitor for a worsening of the condition (efficacy of propranolol in HF has not been demonstrated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prinzmetal variant angina: Beta-blockers without alpha1-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may have increased side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. Alterations in thyroid function tests may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants and children: Considerations when treating infantile hemangioma:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Cardiovascular concerns: Bradycardia and/or hypotension may occur or be worsened; monitor heart rate and blood pressure after propranolol initiation or increase in dose; discontinue treatment if severe (&lt;80 bpm) or symptomatic bradycardia or hypotension (systolic blood pressure &lt;50 mm Hg) occurs. Infants with large facial infantile hemangioma should be investigated for potential arteriopathy associated with PHACE syndrome prior to propranolol therapy; decreases in blood pressure caused by propranolol may increase risk of stroke in PHACE syndrome patients with cerebrovascular anomalies.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Hypoglycemia: May potentiate hypoglycemia and/or mask signs and symptoms. Withhold the dose in infants or children who are not feeding regularly or who are vomiting; discontinue therapy and seek immediate treatment if hypoglycemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Respiratory concerns: May cause bronchospasm. Interrupt therapy in infants or children with lower respiratory tract infection associated with dyspnea or wheezing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Smokers: Cigarette smoking may decrease plasma levels of propranolol by increasing metabolism. Patients should be advised to avoid smoking.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt withdrawal: <b>[US Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. </b> Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214934\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214871\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9829&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Propranolol may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Propranolol. Management: Use a lower initial propranolol dose and be cautious with propranolol dose titration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacidipine: May enhance the hypotensive effect of Propranolol. Lacidipine may increase the serum concentration of Propranolol. Propranolol may decrease the serum concentration of Lacidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rizatriptan: Propranolol may increase the serum concentration of Rizatriptan.  Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Citalopram; Escitalopram; FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zileuton: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ZOLMitriptan: Propranolol may increase the serum concentration of ZOLMitriptan. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214902\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Ethanol may increase or decrease plasma levels of propranolol. Reports are variable and have shown both enhanced as well as inhibited hepatic metabolism (of propranolol). Management: Caution advised with consumption of ethanol and monitor for heart rate and/or blood pressure changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Propranolol serum levels may be increased if taken with food. Protein-rich foods may increase bioavailability; a change in diet from high carbohydrate/low protein to low carbohydrate/high protein may result in increased oral clearance. Management: Tablets (immediate release) should be taken on an empty stomach. Capsules (extended release) may be taken with or without food, but be consistent with regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214888\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Propranolol crosses the placenta and is measurable in the newborn serum following maternal use during pregnancy (Taylor 1981). According to the manufacturer, congenital abnormalities have been reported following maternal use of propranolol. Bradycardia, hypoglycemia, and/or respiratory depression have been observed in neonates following in utero exposure to propranolol at parturition. Reduced birth weight has also been observed following in utero exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are also associated with adverse events in the fetus, infant, and mother (ACOG 2015; Magee 2014). When treatment of hypertension in pregnancy is indicated, beta-blockers may be used. Specific recommendations vary by guideline. Although other agents are preferred (ACOG 2013), use of propranolol may be considered (Magee 2014). Use of propranolol may be considered for some arrhythmias, including SVT, when use of a beta-blocker is needed during pregnancy (ACC/AHA/HRS [Page 2015]; ESC [Regitz-Zagrosek 2011]). Propranolol is recommended for use in controlling hypermetabolic symptoms of thyrotoxicosis in pregnancy (Stagnaro-Green 2011). Propranolol may be used if prophylaxis of migraine is needed in pregnant women; it should be discontinued 2 to 3 days prior to delivery to decrease the risk of adverse events to the fetus/neonate and potential reductions in uterine contraction (Pringsheim 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214889\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of propranolol is 1% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 1 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest milk concentration (0.075 mcg/mL), the estimated daily infant dose via breast milk is 11.25 mcg/kg/day. This milk concentration was obtained following maternal administration of propranolol 1.2 mg/kg/day. Using data collected from three women, the same study found the overall half-life of propranolol in breast milk to be 6.5 &plusmn; 3.4 hours (Smith Livingstone Hooper 1983). Peak milk concentrations are reported to occur between 2 to 3 hours after an oral dose (Bauer 1979).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, propranolol may be compatible with breastfeeding when used at usual doses. Mothers should closely monitor their breastfeeding infants for bradycardia, cyanosis, and hypoglycemia (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214890\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets (immediate release) should be taken on an empty stomach; capsules (extended release) may be taken with or without food, but should always be taken consistently (with food or on an empty stomach). Hemangeol should be administered during or right after a feeding to reduce the risk of hypoglycemia; skip dose if child is not eating or is vomiting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214875\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Acute cardiac treatment: Monitor ECG, heart rate, and blood pressure with IV administration; heart rate and blood pressure with oral administration</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hemangeol: Monitor heart rate and blood pressure for 2 hours after initiation or dose increases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214865\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nonselective beta-adrenergic blocker (class II antiarrhythmic); competitively blocks response to beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic stimulation which results in decreases in heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand. Nonselective beta-adrenergic blockers (propranolol, nadolol) reduce portal pressure by producing splanchnic vasoconstriction (beta<sub>2</sub> effect) thereby reducing portal blood flow. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214884\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Beta-blockade: Oral: 1 to 2 hours; Peak effect: Hypertension: A few days to several weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Immediate release: 6 to 12 hours; Extended-release formulations: ~24 to 27 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 4 L/kg (adults); crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Newborns: 68%; Adults: ~90% (S-isomer primarily to alpha-1 acid glycoprotein; R-isomer primarily to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass effect, hepatically metabolized to active and inactive compounds; the 3 main metabolic pathways include: Aromatic hydroxylation (primarily 4-hydroxylation), N-dealkylation followed by further side-chain oxidation and direct glucuronidation; the 4 primary metabolites include: Propranolol glucuronide, naphthyloxylactic acid, and sulfate and glucuronic acid conjugates of 4-hydroxy propranolol; <b>Note:</b> Aromatic hydroxylation is catalyzed primarily by isoenzyme CYP2D6; side chain oxidation is mainly via CYP1A2, but also CYP2D6; 4-hydroxypropranolol possesses beta-adrenergic receptor blocking activity and is a weak inhibitor of CYP2D6. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~25% reaches systemic circulation due to high first-pass metabolism; oral bioavailability may be increased in Down syndrome children; protein-rich foods increase bioavailability by ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates: Possible increased half-life; Infants (35 to 150 days of age): Median 3.5 hours; Children: 3.9 to 6.4 hours; Adults: Immediate release formulation: 3 to 6 hours; Extended-release formulations: 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Immediate release: Adults: 1 to 4 hours; Infants: &le;2 hours (Hemangeol); Extended release capsule (Inderal XL, InnoPran XL): 12 to 14 hours; Long acting capsule (Inderal LA): 6 hours  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Metabolites are excreted primarily in urine (96% to 99%); &lt;1% excreted in urine as unchanged drug</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214887\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Inderal LA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $2,157.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $2,520.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $3,031.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $3,165.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Inderal XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $906.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $906.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (InnoPran XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $906.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $906.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Propranolol HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $204.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $238.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $298.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $388.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hemangeol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.28 mg/mL (120 mL): $643.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Propranolol HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Propranolol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/5 mL (500 mL): $65.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/5 mL (500 mL): $94.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Propranolol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $40.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $50.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $71.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $174.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $89.67</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214891\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adlock (BD);</li>\n      <li>Anaprilan (RU);</li>\n      <li>Anaprilins (LV);</li>\n      <li>Arteflo (LK);</li>\n      <li>Atensin (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Avlocardyl (FR, VN);</li>\n      <li>Bai Er Luo (CN);</li>\n      <li>Bedranol (AE, BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LB, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Berkolol (HK);</li>\n      <li>Beta-Prograne (IE);</li>\n      <li>Beta-Timelets (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Betabex (BD);</li>\n      <li>Betalol (TH);</li>\n      <li>Betapress (TH);</li>\n      <li>Betascan (TW);</li>\n      <li>Cardiblok (ZA);</li>\n      <li>Cardilol (AE);</li>\n      <li>Cardinol (NZ);</li>\n      <li>Cardinol LA (NZ);</li>\n      <li>Cardispare (ZA);</li>\n      <li>Cardolol (TW);</li>\n      <li>Ciplar (IN);</li>\n      <li>Colliprol (MX);</li>\n      <li>Corbeta (IN);</li>\n      <li>Coriodal (CL);</li>\n      <li>Deralin (AU, IL);</li>\n      <li>Dideral (TR);</li>\n      <li>Dociton (DE);</li>\n      <li>Duranol (PH);</li>\n      <li>Emforal (MT, TR);</li>\n      <li>Farmadral (ID);</li>\n      <li>Frina (GR);</li>\n      <li>Frixopel (PY);</li>\n      <li>Half Beta-Prograne (IE);</li>\n      <li>Hemangiol (CZ, ES, IE, JP, KR);</li>\n      <li>Hipranol (MY);</li>\n      <li>Indenol (KR);</li>\n      <li>Inderal (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CO, CY, DK, EC, EG, ET, GH, GM, GN, GR, GY, IE, IQ, IR, IT, JM, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PE, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SI, SL, SN, SR, SY, TN, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Inderal LA (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PE, PT, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Inderalici (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Indesol (KR);</li>\n      <li>Indever (BD);</li>\n      <li>Indicardin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, QA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Inpanol (HK);</li>\n      <li>Laining (TW);</li>\n      <li>MIDDLEEAST (IL);</li>\n      <li>Normpress (TH);</li>\n      <li>Oposim (AR);</li>\n      <li>Palon (TH);</li>\n      <li>Pranidol (MX);</li>\n      <li>Pranosol (LK);</li>\n      <li>Presin (PY);</li>\n      <li>Presoral (BD);</li>\n      <li>Prestoral (ID);</li>\n      <li>Prolol (IL);</li>\n      <li>Pronol (BD);</li>\n      <li>Propalong (AR);</li>\n      <li>Propayerst (AR);</li>\n      <li>Propra (EE);</li>\n      <li>Propra-Ratiopharm (PL);</li>\n      <li>Propral (FI);</li>\n      <li>Propranolol Eurogenerics (LU);</li>\n      <li>Protolif (EC);</li>\n      <li>Pu Le Xin (CN);</li>\n      <li>Purbloka (ZA);</li>\n      <li>Rebaten LA (BR);</li>\n      <li>Rexigen (ZA, ZW);</li>\n      <li>Slow Deralin (IL);</li>\n      <li>Sumial (ES);</li>\n      <li>Syprol (MT);</li>\n      <li>Tenomal (GR);</li>\n      <li>Tepra (KR);</li>\n      <li>Waucoton (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2877708\"></a>Adler LA, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. <i>Br J Psychiatry</i>. 1986;149:42-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2877708 /pubmed\" target=\"_blank\" id=\"2877708 \">2877708 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8290678\"></a>Adler LA, Peselow E, Rosenthal M, et al, &ldquo;A Controlled Comparison of the Effects of Propranolol, Benztropine, and Placebo on Akathisia: An Interim Analysis,&rdquo; <i>Psychopharmacol Bull</i>, 1993, 29(2):283-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/8290678/pubmed\" target=\"_blank\" id=\"8290678\">8290678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer JH, Pape B, Zajicek J, et al, &quot;Propranolol in Human Plasma and Breast Milk,&quot; <i>Am J Cardiol</i>, 1979, 43(4):860-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/425926/pubmed\" target=\"_blank\" id=\"425926\">425926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6120650\"></a>Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. <i>Am J Med</i>. 1982;72(1):88-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6120650/pubmed\" target=\"_blank\" id=\"6120650\">6120650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Braverman.2013\"></a>Braverman L, Cooper D. <i>Werner &amp; Ingbar's The Thyroid: A Fundamental and Clinical Text</i>. 10th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/Braverman.2013/pubmed\" target=\"_blank\" id=\"Braverman.2013\">Braverman.2013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cameron P, Jelinek G, Everitt I, et al. <i>Textbook of Paediatric Emergency Medicine</i>. 2nd ed. Churchill Livinstone Elsevier; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Pediatric Emergencies. Committee on Drugs, Committee on Drugs, 1996 to 1997, Liaison Representatives, and AAP Section Liaisons,&rdquo; <i>Pediatrics</i>, 1998, 101(1):E13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9734990/pubmed\" target=\"_blank\" id=\"9734990\">9734990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farine M and Arbus G, &ldquo;Management of Hypertensive Emergencies in Children,&rdquo; <i>Pediatr Emerg Care</i>, 1989, 5(1):51-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2652097/pubmed\" target=\"_blank\" id=\"2652097\">2652097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster CA and Aston SJ, &ldquo;Propranolol-Epinephrine Interaction: A Potential Disaster,&rdquo; <i>Plast Reconstr Surg</i>, 1983, 72(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6867180 /pubmed\" target=\"_blank\" id=\"6867180 \">6867180 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, Carcillo J, et al. Pediatric Critical Care. 4th ed. Philadelphia Pennsylvania: Elsevier Mosby; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Tsao G, Sanyal AJ, Grace ND, et al, &ldquo;Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis,&rdquo; <i>Hepatology</i>, 2007, 46(3):922-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/17879356/pubmed\" target=\"_blank\" id=\"17879356\">17879356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geffner DL and Hershman JM, &ldquo;beta-Adrenergic Blockade for the Treatment of Hyperthyroidism,&rdquo; <i>Am J Med</i>, 1992, 93(1):61-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1352658/pubmed\" target=\"_blank\" id=\"1352658\">1352658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7615481\"></a>Gelenberg AJ, Jefferson JW. Lithium tremor. <i>J Clin Psychiatry</i>. 1995;56(7):283-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7615481/pubmed\" target=\"_blank\" id=\"7615481\">7615481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6871565\"></a>Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blocking drugs on speakers' performance and memory.<i> Br J Psychiatry</i>. 1983;142:512-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6871565/pubmed\" target=\"_blank\" id=\"6871565\">6871565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World J Biol Psychiatry</i>. 2013;14(1):2-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23216388/pubmed\" target=\"_blank\" id=\"23216388\">23216388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemangeol (propranolol) [prescribing information]. Parsippany, NJ: Pierre Fabre Pharmaceuticals; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemangiol (propranolol) [product monograph]. Brossard, Quebec, Canada: Pierre-Fabre Dermo-Cosmetique; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo; <i>Circulation </i>, 2006, 113(11):e463-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16549646/pubmed\" target=\"_blank\" id=\"16549646\">16549646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inderal LA (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inderal LA (propranolol) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inderal XL (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Innopran XL (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assun&ccedil;&atilde;o-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. <i>J Clin Psychiatry</i>, 2009, 70(5):627-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/19389331/pubmed\" target=\"_blank\" id=\"19389331\">19389331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4127340\"></a>Kirk L, Baastrup PC, Schou M. Letter: Propranolol treatment of lithium-induced tremor. <i>Lancet</i>. 1973;2(7837):1086-1087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/4127340/pubmed\" target=\"_blank\" id=\"4127340\">4127340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2577308\"></a>Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. <i>Hillside J Clin Psychiatry</i>. 1989;11(2):107-119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2577308/pubmed\" target=\"_blank\" id=\"2577308\">2577308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2906547\"></a>Kramer MS, Gorkin RA, DiJohnson C, Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. <i>Biol Psychiatry</i>. 1988;24(7):823-827.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2906547/pubmed\" target=\"_blank\" id=\"2906547\">2906547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1260604\"></a>Lapierre YD. Control of lithium tremor with propranolol. <i>Can Med Assoc J</i>. 1976;114(7):619-620, 624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1260604/pubmed\" target=\"_blank\" id=\"1260604\">1260604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenauer PK, Pekow P, Wang K, et al, &quot;Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,&rdquo; <i>N Engl J Med</i>, 2005, 353(4):349-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16049209/pubmed\" target=\"_blank\" id=\"16049209\">16049209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luedtke S, Kuhn R, and McCaffrey F, &ldquo;Pharmacologic Management of Supraventricular Tachycardias in Children. Part 2: Atrial flutter, Atrial Fibrillation, and Junctional and Atrial Ectopic Tachycardia,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(11):1347-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9391691/pubmed\" target=\"_blank\" id=\"9391691\">9391691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9562933/pubmed\" target=\"_blank\" id=\"9562933\">9562933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2011. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pickoff AS, Zies L, Ferrer PL, et al, &ldquo;High-dose Propranolol Therapy in the Management of Supraventricular Tachycardia,&rdquo; <i>J Pediatr</i>, 1979, 94(1):144-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/758396/pubmed\" target=\"_blank\" id=\"758396\">758396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16497273\"></a>Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. <i>Biol Psychiatry</i>. 2006;59(11):1071-1077.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16497273/pubmed\" target=\"_blank\" id=\"16497273\">16497273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2 Suppl 2):S1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22683887 /pubmed\" target=\"_blank\" id=\"22683887 \">22683887 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propranolol hydrochloride injection [product monograph]. Boucherville, QC, Canada: Sandoz Canada Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propranolol hydrochloride tablets [prescribing information]. Hayward, CA: Impax Generics; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18340692/pubmed\" target=\"_blank\" id=\"18340692\">18340692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radack K and Deck C, &ldquo;Beta-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease. A Meta-Analysis of Randomized Controlled Trials,&rdquo; <i>Arch Intern Med</i>, 1991, 151(9):1769-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1679624/pubmed\" target=\"_blank\" id=\"1679624\">1679624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25840695/pubmed\" target=\"_blank\" id=\"25840695\">25840695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27521067\"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi 10.1089/thy.2016.0229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo; <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shanks RG, Hadden DR, Lowe DC, et al, &ldquo;Controlled Trial of Propranolol in Thyrotoxicosis,&rdquo; <i>Lancet</i>, 1969, 1(7603):993-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/4181181/pubmed\" target=\"_blank\" id=\"4181181\">4181181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith MT, Livingstone I, Hooper WD, et al, &quot;Propranolol, Propranolol Glucuronide, and Naphthoxylactic Acid in Breast Milk and Plasma,&quot; <i>Ther Drug Monit</i>, 1983, 5(1):87-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6845404/pubmed\" target=\"_blank\" id=\"6845404\">6845404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. <i>Thyroid</i>. 2011;21(10):1081-1125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21787128 /pubmed\" target=\"_blank\" id=\"21787128 \">21787128 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor EA and Turner P, &quot;Anti-hypertensive Therapy With Propranolol During Pregnancy and Lactation,&quot; <i>Postgrad Med J</i>, 1981, 57(669):427-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7312737/pubmed\" target=\"_blank\" id=\"7312737\">7312737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teva-Propranolol [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo; <i>BMJ</i>, 1998, 317(7160):713-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9732338/pubmed\" target=\"_blank\" id=\"9732338\">9732338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wensley DF, Karl T, Deanfield JE, et al, &ldquo;Assessment of Residual Right Ventricular Outflow Tract Obstruction Following Surgery Using the Response to Intravenous Propranolol,&rdquo; <i>Ann Thorac Surg</i>, 1987, 44(6):633-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3689047/pubmed\" target=\"_blank\" id=\"3689047\">3689047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong DG, Spence JD, Lamki L, et al, &ldquo;Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,&rdquo; <i>Lancet</i>, 1986, 1(8488):997-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2871333 /pubmed\" target=\"_blank\" id=\"2871333 \">2871333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Dental Nonsteroidal Anti-inflammatory Drugs and Prostaglandin-Based Drug Interactions, Part Two,&rdquo; <i>Gen Dent</i>, 1992, 40(2):104, 106, 108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1354194 /pubmed\" target=\"_blank\" id=\"1354194 \">1354194 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo; <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7911769 /pubmed\" target=\"_blank\" id=\"7911769 \">7911769 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9829 Version 272.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7254284\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F214907\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F214908\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F214939\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F214911\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F214926\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F214912\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F214913\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F214914\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F214877\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F214862\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F25573739\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F214882\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F214881\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744560\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F214948\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F214869\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F214885\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F214866\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F214934\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F214871\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F214902\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F214873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F214888\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F214889\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F214890\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F214875\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F214865\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F214884\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F214887\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F214891\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9829|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=propranolol-patient-drug-information\" class=\"drug drug_patient\">Propranolol: Patient drug information</a></li><li><a href=\"topic.htm?path=propranolol-pediatric-drug-information\" class=\"drug drug_pediatric\">Propranolol: Pediatric drug information</a></li></ul></div></div>","javascript":null}